© 2022 BioMarin. All rights reserved.

Press Releases

Advanced Search
  • Jul 19, 2004
    Study Demonstrates Substantial Reduction in Phenylalanine Levels in PKU Patients

    BioMarin Pharmaceutical Inc. announced positive results from a pilot clinical study of 6R-BH4 in 20 patients with phenylketonuria (PKU). 6R-BH4 is the active agent in Phenoptin(TM), an...

  • Jun 2, 2004
    Aryplase Demonstrates Statistically Significant Benefit in Primary Endpoint

    BioMarin Pharmaceutical Inc. today announced positive results from its Phase 3 clinical trial of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...

  • May 18, 2004

    BioMarin Pharmaceutical Inc. announced that it has completed the transaction, announced April 20, 2004, to obtain Ascent Pediatrics, a profitable pediatrics business that includes Orapred(R), the...

  • May 3, 2004
    Conference Call and Webcast to be Held Today at 12:00 p.m. EDT (18:00 CEST)

    BioMarin Pharmaceutical Inc. today announced financial results for the first quarter of the fiscal year 2004. The company incurred a net loss of $19.9 million ($0.31 per share) for the quarter...

  • Apr 20, 2004
    Ascent Pediatrics, Inc. Provides BioMarin with Growing Product Revenues and Commercial Infrastructure to Launch its Pipeline of Pediatric Products

    BioMarin Pharmaceutical Inc. today announced that it has signed definitive agreements with Medicis Pharmaceutical Corporation to obtain its Pediatric Business as defined in the transaction...